Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia
Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2002]
|
| In: |
Leukemia and lymphoma
Year: 2002, Jahrgang: 43, Heft: 1, Pages: 149-151 |
| ISSN: | 1029-2403 |
| DOI: | 10.1080/10428190210178 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/10428190210178
|
| Verfasserangaben: | Jolanta Perz, Julian Topaly, Stefan Fruehauf, Manfred Hensel Anthony D. Ho (Department of Internal Medicine V, University of Heidelberg) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1782135200 | ||
| 003 | DE-627 | ||
| 005 | 20220820094006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211214s2002 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428190210178 |2 doi | |
| 035 | |a (DE-627)1782135200 | ||
| 035 | |a (DE-599)KXP1782135200 | ||
| 035 | |a (OCoLC)1341436313 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dengler, Jolanta |d 1972- |e VerfasserIn |0 (DE-588)121586138 |0 (DE-627)705556344 |0 (DE-576)292785291 |4 aut | |
| 245 | 1 | 0 | |a Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia |c Jolanta Perz, Julian Topaly, Stefan Fruehauf, Manfred Hensel Anthony D. Ho (Department of Internal Medicine V, University of Heidelberg) |
| 264 | 1 | |c [2002] | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druckausgabe | ||
| 500 | |a Gesehen am 14.12.2021 | ||
| 520 | |a Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment. | ||
| 650 | 4 | |a Anti Cd20 Antibody | |
| 650 | 4 | |a B-cell Chronic Lymphocytic Leukemia (B-CLL) | |
| 650 | 4 | |a B-cell Prolymphocytic Leukemia (B-PLL) | |
| 650 | 4 | |a Cd20-expression | |
| 650 | 4 | |a Monoclonal Antibody | |
| 650 | 4 | |a Rituximab | |
| 700 | 1 | |a Topaly, Julian |d 1973- |e VerfasserIn |0 (DE-588)124381383 |0 (DE-627)363308237 |0 (DE-576)294146563 |4 aut | |
| 700 | 1 | |a Frühauf, Stefan |d 1964- |e VerfasserIn |0 (DE-588)113078676 |0 (DE-627)618240306 |0 (DE-576)317921320 |4 aut | |
| 700 | 1 | |a Hensel, Manfred |d 1964- |e VerfasserIn |0 (DE-588)1065849729 |0 (DE-627)816878307 |0 (DE-576)425541908 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 43(2002), 1, Seite 149-151 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia |
| 773 | 1 | 8 | |g volume:43 |g year:2002 |g number:1 |g pages:149-151 |g extent:3 |a Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia |
| 856 | 4 | 0 | |u https://doi.org/10.1080/10428190210178 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211214 | ||
| 993 | |a Article | ||
| 994 | |a 2002 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 5 |y j | ||
| 998 | |g 1065849729 |a Hensel, Manfred |m 1065849729:Hensel, Manfred |d 910000 |d 910100 |e 910000PH1065849729 |e 910100PH1065849729 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 113078676 |a Frühauf, Stefan |m 113078676:Frühauf, Stefan |d 910000 |d 910100 |e 910000PF113078676 |e 910100PF113078676 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 124381383 |a Topaly, Julian |m 124381383:Topaly, Julian |d 50000 |e 50000PT124381383 |k 0/50000/ |p 2 | ||
| 998 | |g 121586138 |a Dengler, Jolanta |m 121586138:Dengler, Jolanta |d 910000 |d 910100 |e 910000PD121586138 |e 910100PD121586138 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1782135200 |e 4020216029 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"3 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1782135200"],"doi":["10.1080/10428190210178"]},"relHost":[{"recId":"324746237","disp":"Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemiaLeukemia and lymphoma","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1989/90 -"],"origin":[{"dateIssuedDisp":"1989-","publisher":"Taylor & Francis Group ; Informa Healthcare","publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedKey":"1989"}],"title":[{"title_sort":"Leukemia and lymphoma","title":"Leukemia and lymphoma"}],"part":{"pages":"149-151","year":"2002","volume":"43","text":"43(2002), 1, Seite 149-151","issue":"1","extent":"3"},"id":{"issn":["1029-2403"],"zdb":["2030637-4"],"eki":["324746237"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 08.09.15"]}],"note":["Elektronische Reproduktion der Druckausgabe","Gesehen am 14.12.2021"],"person":[{"role":"aut","family":"Dengler","given":"Jolanta","display":"Dengler, Jolanta"},{"given":"Julian","display":"Topaly, Julian","family":"Topaly","role":"aut"},{"role":"aut","given":"Stefan","display":"Frühauf, Stefan","family":"Frühauf"},{"role":"aut","display":"Hensel, Manfred","given":"Manfred","family":"Hensel"},{"family":"Ho","given":"Anthony Dick","display":"Ho, Anthony Dick","role":"aut"}],"recId":"1782135200","name":{"displayForm":["Jolanta Perz, Julian Topaly, Stefan Fruehauf, Manfred Hensel Anthony D. Ho (Department of Internal Medicine V, University of Heidelberg)"]},"origin":[{"dateIssuedDisp":"[2002]","dateIssuedKey":"2002"}],"language":["eng"],"title":[{"title_sort":"Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia","title":"Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia"}]} | ||
| SRT | |a DENGLERJOLLEVELOFCD22002 | ||